-+ 0.00%
-+ 0.00%
-+ 0.00%
China Medical System Unit Dermavon Enrolls First Patient in China Phase III Vitiligo Drug Trial
Share
Listen to the news
China Medical System Unit Dermavon Enrolls First Patient in China Phase III Vitiligo Drug Trial
  • China Medical System subsidiary Dermavon enrolled the first patient in its Chinese Phase III povorcitinib vitiligo trial on Nov. 19, 2026.
  • The trial targets approximately 174 adults with non-segmental vitiligo across about 44 Chinese research centers to evaluate efficacy and safety.
  • The oral JAK1 inhibitor has received breakthrough therapy designation from China’s drug regulator.
  • Dermavon is seeking a separate listing on the Hong Kong Stock Exchange’s Main Board.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190704PRIMZONEFULLFEED9881254) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending